研究单位：[1]Women's Hospital School of Medicine Zhejiang University,Hangzhou,Zhejiang,China,310000[2]Tongji Hospital, Huazhong University of Science and Technology,Wuhan,Hubei,China[3]Qilu Hospital of Shandong University,Jinan,Shandong,China[4]Peking University Peoples Hospital,Beijing,China[5]Sun Yat-Sen University Cancer Hospital,Guangzhou,China[6]Obstetrics & Gynecology Hospital of Fudan University,Shanghai,China[7]Shanghai First Maternity and Infant Hospital,Shanghai,China
研究目的：
This is a prospective, multicenter, randomized phase III trial among women with endometrioid adenocarcinoma with high-intermediate and intermediate risk features to investigate the role of integrated genomic-pathologic classification to determine if participants should receive no adjuvant therapy, vaginal brachytherapy, external beam radiotherapy or chemo-radiation therapy based on molecular features as compared to standard radiation therapy.
